Multiple Myeloma | Specialty

Daratumumab Triplet Reduces Risk of Progression by 63% in Myeloma

June 12th 2016

Combining the CD38-targeted antibody daratumumab with lenalidomide and dexamethasone reduced the risk of disease progression by 63% versus lenalidomide and dexamethasone alone in patients with relapsed/refractory multiple myeloma, according to findings from the phase III POLLUX (MMY3003) trial.

Daratumumab Combo Shows Unprecedented PFS Benefit in Multiple Myeloma

June 5th 2016

Adding daratumumab to bortezomib and dexamethasone reduced the risk of progression or death by 61%, and doubled response rates compared with the standard 2-drug regimen alone for patients with recurrent or refractory multiple myeloma.

Dr. Palumbo on CASTOR Trial Results in Multiple Myeloma

June 5th 2016

Antonio Palumbo, MD, chief, Myeloma Unit, Department of Oncology, Section of Hematology, University of Torino, Italy, discusses the phase III results of the CASTOR trial, which was a randomized controlled study examining the efficacy of daratumumab (Darzalex), bortezomib (Velcade), and dexamethasone versus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma.

Dr. Cavo on Upfront ASCT in Multiple Myeloma

June 5th 2016

Michele Cavo, MD, professor, Seràgnoli Institute of Hematology Bologna University School of Medicine, discusses the results of the phase III EMN02/HO95 MM trial, which compared the efficacy of upfront autologous stem cell transplantation versus novel agent-based therapy for the treatment of patients with multiple myeloma.

Carfilzomib/Pomalidomide Regimen Warrants Further Investigation in Refractory Multiple Myeloma

June 4th 2016

A regimen consisting of carfilzomib, pomalidomide, and dexamethasone merits further investigation for the treatment of patients with multiple myeloma whose disease progresses while on lenalidomide in the earlier stages of disease.

Isatuximab Monotherapy Effective for Heavily Pretreated Myeloma

June 4th 2016

The anti-CD38 monoclonal antibody isatuximab showed promising signs of activity as a single-agent for patients with heavily pretreated relapsed/refractory multiple myeloma.

Dr. Madhav Dhodapkar on IMiD-based Combinations in Multiple Myeloma

June 2nd 2016

CHMP Recommends Expanding Carfilzomib Approval in Multiple Myeloma

May 27th 2016

Carfilzomib (Kyprolis) has received a positive recommendation from the EMA's Committee for Medicinal Products for Human Use for use in combination with dexamethasone alone as a treatment for patients with multiple myeloma following at least 1 prior therapy.

Daratumumab Approved in Europe for Multiple Myeloma

May 23rd 2016

The European Commission has granted conditional marketing approval to daratumumab (Darzalex) for the treatment of patients with relapsed/refractory multiple myeloma previously treated with a proteasome inhibitor and an immunomodulatory agent who progressed on their last therapy.

Second Daratumumab Triplet Delays Disease Progression in Myeloma

May 20th 2016

Adding daratumumab (Darzalex) to lenalidomide and dexamethasone reduced the risk of disease progression by 63% in patients with relapsed/refractory multiple myeloma in the phase III POLLUX trial.

Stem Cell Transplant Continues to Show Benefit in 'Novel-Agent Era' of Multiple Myeloma

May 19th 2016

Early findings from a phase III clinical trial suggest that patients with multiple myeloma who receive upfront autologous stem cell transplant survive longer without disease progression than those who receive chemotherapy alone.

Elotuzumab Approved in Europe for Multiple Myeloma

May 12th 2016

The European Commission approved elotuzumab (Empliciti) for use in combination with lenalidomide (Revlimid) and dexamethasone for patients with multiple myeloma following progression on at least 1 prior therapy.

APRIL/BCMA Targeted Agent May Block Tumor Growth, Drug Resistance in Myeloma

May 5th 2016

Kenneth Anderson, MD, PhD, discusses the role of APRIL/BCMA and what potential the targeted agent BION-1301 may have in blocking multiple myeloma cell proliferation, as well as reducing drug resistance and immunosuppression in the tumor microenvironment.

Leonie de Best on Validation of EMC92/SKY92 Signature in Myeloma

May 4th 2016

Leonie de Best, MSc2, chief operating officer, SkylineDX, discusses the HOVON-87/NMSG-18 study, which demonstrated the validation of the EMC92/SKY92 signature for elderly patients with newly diagnosed multiple myeloma.

Early Intervention With Lenalidomide Examined in Smoldering Myeloma

May 2nd 2016

In an ongoing randomized phase III trial, researchers are looking at lenalidomide (Revlimid) compared with observation in patients with asymptomatic high-risk smoldering multiple myeloma.

NEJM Data Illuminate Efficacy of Oral Ixazomib Triplet in Myeloma

April 28th 2016

Adding ixazomib (Ninlaro) to lenalidomide (Revlimid) and dexamethasone reduced the risk of disease progression or death by 26% compared with lenalidomide and dexamethasone alone for patients with relapsed/refractory multiple myeloma.

Jagannath Hails "Exciting" Era in Treating Myeloma

April 5th 2016

Sundar Jagannath, MD, discusses emerging agents in multiple myeloma he is most excited about, sequencing challenges, and the role for personalized medicine in the disease.

CHMP Recommends Approval of Daratumumab for Multiple Myeloma

April 4th 2016

Single-agent daratumumab (Darzalex) for the treatment of patients with relapsed/refractory multiple myeloma previously treated with a proteasome inhibitor and an immunomodulatory agent has received a positive recommendation from the Committee for Medicinal Products for Human Use.

Dr. Rajkumar on Significance of SWOG S0777 Study for Multiple Myeloma

April 4th 2016

S. Vincent Rajkumar, MD, professor of Medicine at Mayo Clinic, discusses the significance of the phase III SWOG S0777 study, which looked at bortezomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with previously untreated multiple myeloma.

NCCN Broadens Myeloma Diagnostic Criteria, Recommends Novel Agents

April 2nd 2016

The updated NCCN myeloma guideline broadens the diagnostic criteria for active disease and integrates novel therapies into the treatment paradigm.